Anzeige
Meldung des Tages: Double Mer Projekt: SAGA zweites strategisches Standbein – Uran für das KI-Zeitalter

NewcelX Aktie News

Aktie
WKN:  A41SEM ISIN:  CH1442297896 US-Symbol:  NCEL Branche:  Biotechnologie Land:  Schweiz
2,68 $
+0,02 $
+0,75%
2,2830 € 22.01.26
Depot/Watchlist
Marktkapitalisierung *
903,01 Tsd. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

NewcelX News

15.04.25 - PR Newswire
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-​Induced Reward in Animal Models PR Newswire
10.03.25 - PR Newswire
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics CEO Issues Letter to Shareholders PR Newswire
27.02.25 - PR Newswire
NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform
NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-​Sulfonamide Dual Orexin Receptor Agonist Platform PR Newswire
25.02.25 - PR Newswire
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment PR Newswire
10.02.25 - PR Newswire
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
NLS Pharmaceutics and Kadimastem Unveil Multi-​Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies PR Newswire
31.01.25 - PR Newswire
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics PR Newswire
30.01.25 - PR Newswire
NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting
NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting PR Newswire
28.01.25 - PR Newswire
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence PR Newswire

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »